Metropolis Healthcare Limited - Q1FY26 Business Update

Metropolis Healthcare Limited has provided a business update for the quarter ended June 30, 2025.

This update seeks to provide an overall summary of the operating performance and demand trends witnessed during the quarter ended June 30, 2025. A detailed information update will follow once the Board of Directors approves the financial results for Q1FY26.

While the healthcare industry experienced a surprising slowdown in Q4FY25, it appears to be a seasonal and not a structural issue in the industry. The April to June period has marked a return to normalized activity. Competition dynamics remains unchanged, and we continue to believe that Metropolis has the ability to keep growing well organically on the back of patients who need quality results for critical illness. Integrations of recent acquisitions are progressing as planned.

Key highlights of Q1FY26 (Consolidated):

1. Revenue growth is approx. 23% on a Y-o-Y basis including revenues from Core Diagnostics (Core) (full quarter), Scientific Pathology (Scientific), Agra (consolidated from 17th June, 2025) and Dr. Ahuja's Pathology & Imaging Center (DAPIC), Dehradun (consolidated from 23rd May, 2025).

2. Post-acquisition, Core has moved from breakeven position in Q4FY25 to a single digit positive margin trajectory, while DAPIC, Dehradun and Scientific, Agra outperformed the company average on margin performance. On a consolidated level, MHL EBIDTA margin percentage is slightly lower due to consolidation of Core.

3. Specialty revenues witness a growth of approx. 35%+ on a Y-o-Y basis on account of consolidation of Core which is largely high-end specialized Oncology Testing.

Key highlights of Q1FY26 (Excluding acquisition of Core, DAPIC and Scientific):

1. Revenues grew by approximately 13% Y-o-Y, driven by an increase in patient and test volumes, a favorable shift in product mix, and improved realizations.

2. B2C revenues registered a Y-o-Y growth of around 15%.

3. The TruHealth Wellness and Specialty segments recorded Y-o-Y growth of ~20% and ~15%, respectively, in Q1FY26.

4. EBITDA for the current quarter improved on a Q-o-Q on account of increased throughput, operational efficiencies and operating leverage and remained in line with the same period last year.

5. The Company is debt free.

The quarterly business update is on a consolidated basis. The financial results of Q1FY26 are subject to review by Auditors.

Shares of Metropolis Healthcare Limited was last trading in BSE at Rs. 1773.90 as compared to the previous close of Rs. 1735.10. The total number of shares traded during the day was 4227 in over 532 trades.

The stock hit an intraday high of Rs. 1785.00 and intraday low of 1736.30. The net turnover during the day was Rs. 7472082.00.

Source : Equity Bulls

Keywords

MetropolisHealthcare INE112L01020 HealthcareServices Q1FY26 BusinessUpdate